These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 22853728)
1. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728 [TBL] [Abstract][Full Text] [Related]
2. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Ozkan E; Aras G; Kucuk NO Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202 [TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605 [TBL] [Abstract][Full Text] [Related]
6. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Trybek T; Kowalska A; Lesiak J; Młynarczyk J Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108 [TBL] [Abstract][Full Text] [Related]
7. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259 [TBL] [Abstract][Full Text] [Related]
8. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody. Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510 [TBL] [Abstract][Full Text] [Related]
9. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540 [TBL] [Abstract][Full Text] [Related]
10. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
11. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190 [TBL] [Abstract][Full Text] [Related]
12. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617 [TBL] [Abstract][Full Text] [Related]
13. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels. Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014 [TBL] [Abstract][Full Text] [Related]
14. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome). Ranade R; Kand P; Basu S Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373 [TBL] [Abstract][Full Text] [Related]
15. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959 [TBL] [Abstract][Full Text] [Related]
16. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245 [TBL] [Abstract][Full Text] [Related]
17. Liu J; Liu B; Yu Y; Chao F; Liu Y; Han X Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843 [TBL] [Abstract][Full Text] [Related]
18. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan? Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923 [TBL] [Abstract][Full Text] [Related]
19. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan. Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187 [TBL] [Abstract][Full Text] [Related]
20. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]